The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
Novo Nordisk Pharma said on February 21 that it is preparing for the NHI price listing of a 2 mg version of its once-weekly GLP-1 agent Ozempic (semaglutide), which has been hit by supply restrictions due to GMP issues detected…
To read the full story
Related Article
- Novo Nordisk Begins Normal Shipments for Ozempic in Japan
January 17, 2024
- Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
December 14, 2023
- Novo Nordisk to Quit Ozempic’s Single-Dose Devices, Focus on Multi-Dose Pen
November 17, 2023
- 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
- Trulicity, Rybelsus Might Gain Ground in GLP-1 Market amid Ozempic Supply Woes
March 2, 2022
- Ozempic Shipment Suspension Expected from March: Novo
March 1, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
BUSINESS
- Bayer/Santen to Launch Eylea Bio-AG on February 2
January 9, 2026
- Nxera Bags Japan, Select APAC Rights to Santhera’s DMD Therapy
January 9, 2026
- Keio Offshoot Taps Alfresa Know-How for Cell Therapy Push, Bets on Dual iPS Strategy
January 9, 2026
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Rakuten Ramps Up Photoimmunotherapy PIII with Financing, Eyes US Filing in 2028
January 9, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…